Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats

Behavioural Brain Research

Volumn 225, Issue 2, 2011, Pages 603-609

  Chauhan, Anjali ^a   Sharma, Uma ^a   Jagannathan, N R ^a   Reeta, K H ^a   Gupta, Yogendra Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Diffusion weighted magnetic resonance imaging; Ischemic stroke; Middle cerebral artery occlusion; Neuroprotection; Rapamycin

Indexed keywords

CYCLOSPORIN A; GLUTATHIONE; MALONALDEHYDE; MYELOPEROXIDASE; NITRIC OXIDE; PLACEBO; RAPAMYCIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN LEVEL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; FIBRINOLYTIC THERAPY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; RISK FACTOR; STROKE; TREATMENT PLANNING;

ANIMALS; BRAIN; BRAIN ISCHEMIA; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HAND STRENGTH; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MALONDIALDEHYDE; NEUROIMAGING; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; OXIDATIVE STRESS; PEROXIDASE; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; SIROLIMUS;

EID: 80052965909     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.08.035     Document Type: Article

References (52)

1. Donnan G.A., Fisher M., Macleod M., Davis S.M. Stroke. Lancet 2008, 371:1612-1623.
2. Phillis J.W., O'Regan M.H. The role of phospholipases, cyclooxygenases, and lipoxygenases in cerebral ischemic/traumatic injuries. Crit Rev Neurobiol 2003, 15:61-90.
3. Mattson M.P., Culmsee C., Yu Z.F. Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res 2000, 301:173-187.
4. Zhuo M., Holtzman D.M., Li Y., Osaka H., DeMaro J., Jacquin M., et al. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci 2000, 15(20):542-549.
5. Gupta Y.K., Chauhan A. Potential of immunosuppressive agents in cerebral ischaemia. Indian J Med Res 2011, 133:15-26.
6. Shiga Y., Onodera H., Matsuo Y., Kogure K. Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Res 1992, 595:145-148.
7. Sharkey J., Butcher S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischemia. Nature 1994, 71:336-339.
8. de Mattos A.M., Olyaei A.J., Bennett W.M. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000, 35:333-346.
9. Wijdicks E.F., Wiesner R.H., Krom R.A. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995, 45:1962-1964.
10. Eidelman B.H., Abu-Elmagd K., Wilson J., Fung J.J., Alessiani M., Jain A., et al. Neurologic complications of FK 506. Transplant Proc 1991, 23:3175-3178.
11. Kamada Y., Sekito T., Ohsumi Y. Autophagy in yeast: a TOR-mediated response to nutrient starvation. Curr Top Microbiol Immunol 2004, 279:73-84.
12. Erlich S., Alexandrovich A., Shohami E., Pinkas-Kramarski R. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis 2007, 26:86-93.
13. Caccamo A., Majumder S., Richardson A., Strong R., Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: effects on cognitive impairments. J Biol Chem 2010, 285:13107-13120.
14. Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D.J., et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008, 14:843-848.
15. Koizumi J., Yoshida Y., Nazakawa T., Ooneda G. Experimental studies of ischemic bran edema: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke 1986, 8:1-8.
16. Gupta Y.K., Briyal S., Sharma U., Jagannathan N.R., Gulati A. Effect of endothelin antagonist (TAK-044) on cerebral ischemic volume, oxidative stress markers and neurobehavioral parameters in the middle cerebral artery occlusion model of stroke in rats. Life Sci 2005, 77:15-27.
17. Sinha K., Chaudhary G., Gupta Y.K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 2002, 71:655-665.
18. Sinha K., Degaonkar M.N., Jagannathan N.R., Gupta Y.K. Effect of melatonin on ischemia reperfusion injury induced by middle cerebral artery occlusion in rats. Eur J Pharmacol 2001, 5(428):185-192.
19. Gupta Y.K., Sinha K., Chaudhary G., Jagannathan N.R. Protective effect of adenosine against neuronal injury induced by middle cerebral artery occlusion in rats as evidenced by diffusion-weighted imaging. Pharmacol Biochem Behav 2002, 72:569-574.
20. Tatlisumak T., Carano R.A.D., Takano K., Sotak C.H., Fisher H. A novel endothelium antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion a diffusion and perfusion MRI study. Stroke 1998, 29:850-857.
21. Moran P.M., Higgins L.S., Cordel B., Moser P.C. Age related learning deficits in transgenic mice expressing the 721-amino acid isoform of human beta-amyloid precursor protein. Proc Natl Acad Sci USA 1995, 92:5341-5345.
22. Chaudhary G., Sinha K., Gupta Y.K. Protective effect of exogenous administration of alpha-tocopherol in middle cerebral artery occlusion model of cerebral ischemia in rats. Fundam Clin Pharmacol 2003, 17:703-707.
23. Okhawa H., Ohishi N., Yagi K. Assay of lipid peroxides in animals tissue by thiobarbituraic acid reaction. Anal Biochem 1979, 95:351-358.
24. Ellman G.L. Tissue sulphyldryl groups. Arch Biochem Biophys 1959, 82:70-77.
25. Tunçtan B., Uludag O., Altug S., Abacioglu N. Effects of nitric oxide synthase inhibition in lipopolysaccharide-induced sepsis in mice. Pharmacol Res 1998, 38:405-411.
26. Suzuki K., Ota H., Sasagawa S., Tatsuichiro S., Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leucocytes. Anal Biochem 1982, 127:346-350.
27. Gupta Y.K., Briyal S. Animal models of cerebral ischemia for evaluation of drugs. Indian J Physiol Pharmacol 2004, 48:379-394.
28. Ginsberg M.D. The new language of cerebral ischemia. Am J Neuroradiol 1997, 18:1435-1445.
29. Corbett D., Nurse S. The problem of assessing effective neuroprotection in experimental cerebral ischemia. Prog Neurobiol 1998, 54:531-548.
30. Schilichting C.L.R., Lima K.C.M., Cestari L.A., Sekiyama J.Y., Silva F.M., Milani H. Validation of a simple and inexpensive method for the quantitation of infarct in the rat brain. Braz J Med Biol Res 2004, 37:511-521.
31. Spratt N.J., Fernandez J., Chen M., Rewell S., Cox S., van Raay L., et al. Modification of the method of thread manufacture improves stroke induction rate and reduces mortality after thread-occlusion of the middle cerebral artery in young or aged rats. J Neurosci Methods 2006, 155:285-290.
32. Hoehn-Berlage M., Norris D.G., Kohno K., Mies G., Leibfritz D., Hossmann K.A. Evolution of regional changes in apparent diffusion coefficient during focal ischemia of rat brain: the relationship of quantitative diffusion NMR imaging to reduction in cerebral blood flow and metabolic disturbances. J Cereb Blood Flow Metab 1995, 15:1002-1011.
33. Kohno K., Hoehn-Berlage M., Mies G., Back T., Hossmann K.-A. Relationship between diffusion-weighted magnetic resonance images, cerebral blood flow, and energy state in experimental brain infarction. Magn Reson Imaging 1995, 13:73-80.
34. Kohno K., Back T., Hoehn-Berlage M., Hossmann K.A. A modified rat model of middle cerebral artery thread occlusion under electrophysiological control for magnetic resonance investigations. Magn Reson Imaging 1995, 13:65-71.
35. Lo E.H., Pierce A.R., Mandeville J.B., Rosen B.R. Neuroprotection with NBQX in rat focal cerebral ischemia. Effects on ADC probability distribution functions and diffusion-perfusion relationships. Stroke 1997, 28:439-446.
36. Chaudhary G., Sharma U., Jagannathan N.R., Gupta Y.K. Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats. Clin Exp Pharmacol Physiol 2003, 30:399-404.
37. El-Ani D., Stav H., Guetta V., Arad M., Shainberg A. Rapamycin (sirolimus) protects against hypoxic damage in primary heart cultures via Na(+)/Ca(2+) exchanger activation. Life Sci 2011, 89:7-14.
38. Carloni S., Buonocore G., Balduini W. Protective role autophage in neonatal hypoxia-ischemia induced brain injury. Neurobiol Dis 2008, 32:329-339.
39. Pan T., Kondo S., Zhu W., Xie W., Jankovic J., Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis 2008, 32:16-25.
40. Crews L., Spencer B., Desplats P., Patrick C., Paulino A., Rockenstein E., et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 2010, 5:e9313.
41. Sarkar S., Krishna G., Imarisio S., Saiki S., O'Kane C.J., Rubinsztein D.C. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 2008, 17:170-178.
42. Fox J.H., Connor T., Chopra V., Dorsey K., Kama J.A., Bleckmann D., et al. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Mol Neurodegener 2010, 5:26.
43. Khurana V., Lu Y., Steinhilb M.L., Oldham S., Shulman J.M., Feany M.B. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol 2006, 16:230-241.
44. Berger Z., Ravikumar B., Menzies F.M., Oroz L.G., Underwood B.R., Pangalos M.N., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006, 15:433-442.
45. Behn C., Araneda O.F., Llanos A.J., Celedón G., González G. Hypoxia-related lipid peroxidation: evidences, implications and approaches. Respir Physiol Neurobiol 2007, 158:143-150.
46. Weston R.M., Jones N.M., Jarrott B., Callaway J.K. Inflammatory cell infiltration after endothelin-1-induced cerebral ischemia: histochemical and myeloperoxidasecorrelation with temporal changes in brain injury. J Cereb Blood Flow Metab 2007, 27:100-114.
47. Liu Y.X., Jin L.M., Zhou L., Xie H.Y., Jiang G.P., Chen H., et al. Sirolimus attenuates reduced-size liver ischemia-reperfusion injury but impairs liver regeneration in rats. Dig Dis Sci 2010, 55:2255-2262.
48. Parada B., Reis F., Figueiredo A., Nunes P., Teixeira-Lemos E., Garrido P., et al. Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU Int 2011, 107:135-143.
49. Buisson A., Margaill I., Callebert J., Plotkine M., Boulu R.G. Mechanisms involved in the neuroprotective activity of a nitric oxide synthase inhibitor during focal cerebral ischemia. J Neurochem 1993, 61:690-696.
50. Beckman J.S., Beckman T.W., Chen J. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990, 87:1620-1624.
51. Veltkamp R., Rajapakse N., Robins G., Puskar M., Shimizu K., Busija D. Transient focal ischemia increases endothelial nitric oxide synthase in cerebral blood vessels. Stroke 2002, 33:2704-2710.
52. Tuñón M.J., Sánchez-Campos S., Gutiérrez B., Culebras J.M., González-Gallego J. Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes. Biochem Pharmacol 2003, 66:439-445.